

Ctexli

Dubai · access guide

How to access Ctexli for cerebrotendinous xanthomatosis from Dubai: 2026 emirate pathway via Mediclinic City, American Hospital, and SSMC referral | Reserve Meds

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Dubai's CTX patient population is small but real, captured at Mediclinic City Hospital, American Hospital Dubai, and Al Jalila Children's Specialty Hospital for paediatric cases. Adult metabolic neurology in Dubai routinely cross-refers complex genetics cases to SSMC or CCAD in Abu Dhabi. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement, into the Dubai emirate.

Why Ctexli, why now

Ctexli received FDA approval in February 2024 as the first labelled treatment for CTX, paediatric and adult. CTX is a recessive bile-acid synthesis disorder driven by CYP27A1 mutations, with progressive neurologic deterioration, tendon xanthomas, juvenile cataracts, and early atherosclerosis if untreated. EDE has not yet domestically registered Ctexli, so the Dubai pathway is named-patient import.

What Ctexli is, in plain language

Ctexli is oral chenodiol capsules. It replaces the bile acid the patient's enzyme cannot produce and restores feedback suppression of cholestanol synthesis. It does not reverse damage already done. It slows or halts progression and lowers cholestanol. Weight-based dosing, three times daily with food, lifelong.

Eligibility at a Dubai metabolic-genetics or neurology clinic

Required: biallelic CYP27A1 pathogenic variants on genetics, plus elevated plasma cholestanol. Al Jalila Children's runs paediatric metabolic-genetics; Mediclinic City and American Hospital Dubai handle adult neurology. SSMC and CCAD in Abu Dhabi remain the cross-emirate referral for complex confirmation.

The Dubai prescribing and supply picture

Ctexli is not EDE-registered as of 2026. Access is via EDE-approved named-patient import filed from the Dubai treating clinic, with DHA acknowledgment as required. Reserve Meds coordinates the import file, prescription chain, and temperature-controlled US or EU sourcing into the emirate.

Cost band

USD 150K-220K annual per patient (AED 550K-810K), weight-dependent, lifelong. DHA Saada coverage path applies to Emirati nationals in Dubai under rare-disease provision case-by-case; private insurance typically requires pre-authorisation with genetics report and treating-specialist letter.

What to expect, week-by-week

Weeks 0 to 4: confirm diagnosis, prescription, EDE import filing through Dubai pharmacy. Weeks 4 to 8: shipment arrives, initiation under metabolic or neurology supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, tolerability monitored. Month 6 and 12: full metabolic-neurologic reassessment and MRI white-matter.

When Ctexli is the wrong drug

No biallelic CYP27A1 means not this drug. Normal cholestanol means diagnosis in doubt. Advanced neurologic damage means stabilisation goal, not reversal; family counselling required. Pregnancy data limited; contraception required for women of childbearing age.

Closing

Reserve Meds runs the Ctexli import file from the Dubai metabolic-genetics or neurology referral through EDE named-patient authorisation, US or EU sourcing, and delivered emirate supply. Clinical decisions remain with your treating metabolic specialist or neurologist.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemed.com · hello@reservemed.com